Assenagon Asset Management S.A. Boosts Stock Position in GoodRx Holdings, Inc. $GDRX

Assenagon Asset Management S.A. lifted its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 275.0% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 517,576 shares of the company’s stock after acquiring an additional 379,546 shares during the period. Assenagon Asset Management S.A.’s holdings in GoodRx were worth $1,014,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in GDRX. Lazard Asset Management LLC lifted its stake in GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock valued at $85,000 after acquiring an additional 5,201 shares during the period. Brevan Howard Capital Management LP raised its holdings in shares of GoodRx by 7.7% during the third quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after purchasing an additional 6,842 shares during the last quarter. Hirtle Callaghan & Co LLC lifted its position in GoodRx by 60.3% during the fourth quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after purchasing an additional 6,869 shares during the period. Tower Research Capital LLC TRC lifted its position in GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after purchasing an additional 7,580 shares during the period. Finally, Quarry LP purchased a new stake in GoodRx in the third quarter worth approximately $33,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Weiss Ratings lowered shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 20th. TD Cowen upped their price objective on GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. The Goldman Sachs Group reiterated a “neutral” rating and set a $3.50 target price on shares of GoodRx in a research report on Friday, May 8th. Finally, Citigroup boosted their price target on GoodRx from $3.50 to $4.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.81.

GoodRx Trading Down 0.3%

GDRX opened at $3.05 on Friday. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of 50.84, a P/E/G ratio of 1.42 and a beta of 1.60. GoodRx Holdings, Inc. has a one year low of $1.77 and a one year high of $5.81. The stock’s 50 day moving average price is $2.67 and its 200-day moving average price is $2.48. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.47 and a current ratio of 1.47.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, hitting analysts’ consensus estimates of $0.07. The business had revenue of $194.01 million for the quarter, compared to analyst estimates of $185.40 million. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the company posted $0.09 earnings per share. On average, equities analysts forecast that GoodRx Holdings, Inc. will post 0.17 EPS for the current year.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.